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and adherence tools to manage Parkinson’s
disease (SMART-PD): study protocol for a
randomised controlled trial (v7; 15 August 2014)
Rashmi Lakshminarayana1*, Duolao Wang2, David Burn3, K Ray Chaudhuri4, Gemma Cummins5, Clare Galtrey6,
Bruce Hellman1, Suvankar Pal7, Jon Stamford8, Malcolm Steiger9, Adrian Williams10 and The SMART-PD InvestigatorsAbstract
Background: Nonadherence to treatment leads to suboptimal treatment outcomes and enormous costs to the
economy. This is especially important in Parkinson’s disease (PD). The progressive nature of the degenerative process,
the complex treatment regimens and the high rates of comorbid conditions make treatment adherence in PD a
challenge. Clinicians have limited face-to-face consultation time with PD patients, making it difficult to comprehensively
address non-adherence. The rapid growth of digital technologies provides an opportunity to improve adherence and
the quality of decision-making during consultation. The aim of this randomised controlled trial (RCT) is to evaluate the
impact of using a smartphone and web applications to promote patient self-management as a tool to increase
treatment adherence and working with the data collected to enhance the quality of clinical consultation.
Methods/Design: A 4-month multicentre RCT with 222 patients will be conducted to compare use of a
smartphone- and internet-enabled Parkinson’s tracker smartphone app with treatment as usual for patients with
PD and/or their carers. The study investigators will compare the two groups immediately after intervention.
Seven centres across England (6) and Scotland (1) will be involved. The primary objective of this trial is to assess
whether patients with PD who use the app show improved medication adherence compared to those receiving
treatment as usual alone. The secondary objectives are to investigate whether patients who receive the app and
those who receive treatment as usual differ in terms of quality of life, quality of clinical consultation, overall disease state
and activities of daily living. We also aim to investigate the experience of those receiving the intervention by conducting
qualitative interviews with a sample of participants and clinicians, which will be administered by independent researchers.
Trial registration: ISRCTN45824264 (registered 5 November 2013)
Keywords: Long-term conditions, m-health, Mobile application, Parkinson’s disease, Self-managementBackground
Parkinson’s disease
Parkinson’s disease (PD) is a degenerative movement
disorder affecting 1% to 2% of the population over 60
years of age [1]. In one study on incidence rates, re-
searchers reported that 0.5% of patients were diagnosed
before the age of 40 years, 3.5% before the age of 50
years and more than 60% between the ages of 65 and 79Correspondence:
1uMotif Ltd, London, UK
Full list of author information is available at the end of the article
© 2014 Lakshminarayana et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.years [2]. The core motor features of PD comprise com-
binations of bradykinesia, resting tremor, rigidity, flexed
posture, ‘freezing’ and loss of postural reflexes [3]. PD is
a disabling condition with significant impact on quality
of life (QoL) [4]. Notably, nonmotor symptoms of PD,
such as dementia, sleep disturbances, depression and
falls, may also have a significant negative impact on
QoL [5]. Comorbidity is common in PD. Longitudinal
studies have shown that people with PD have a three to
six times higher risk of developing dementia than do
people of the same age who do not have PD [6,7]. PD isd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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society. Increases in physician and drug costs and longer
hospital admissions compared to age- and sex-matched
controls have also been reported [8].
Complexity of treatment
Managing both motor and non-motor symptoms of PD
translates into complex treatment regimes. Treatment regi-
mens are planned based on the stage of the illness- early or
late- and on the type and mix of nonmotor symptoms [9].
The risk of side effects from treatment adds to the com-
plexity of managing PD (Table 1). In early stages of the dis-
ease, patients usually take a single drug [9,10] but in later
stages of the disease more than half of the patients with PD
take two to three drugs three to four times daily [11,12].
Treatment nonadherence
Adherence to long-term therapies in the general population
is around 50% in the developed world [13]. Nonadherence
results in failed treatment outcomes and $100 billion spent
each year worldwide on avoidable hospitalizations [14].
There are various predictors of medication nonadherence,
including the following ones set forth by Osterberg and
Blaschke [15]:
 Presence of psychological problems, particularly
depressionTable 1 Current available pharmacological treatment and
side effects for early and late Parkinson’s diseasea,b
Therapy Risk of side effects
Motor
complications
Other side
effects
Adjuvant therapy for early PD
Levodopa ↑** ↑***
Dopamine agonists ↓ ↑
MAO-B inhibitors ↓ ↑
β-adrenergic antagonists Lack of evidence
Amantadine Lack of evidence
Anticholinergics Lack of evidence
Modified-release levodopa ↑ ↑
Adjuvant therapy for late PD
Dopamine agonists ↓ ↑
MAO-B inhibitors ↓ ↑
COMT inhibitors ↓ ↑
Amantadine ↓ ↑
Apomorphine ↓ ↑
Modified-release levodopa ↓ ↑
aAdapted from National Institute for Health and Care Excellence (NICE) [9].
bCOMT, Catechol-O-methyltransferase; MAO-B, Monoamine oxidase B; PD,
Parkinson’s disease. ↑** Evidence of increased motor complications/other adverse
events. ↓*** Evidence of reduced motor complications/other adverse events. Presence of cognitive impairment
 Treatment of asymptomatic disease
 Inadequate follow-up or discharge planning
 Side effects of medication
 Patient’s lack of belief in the benefit of treatment
 Patient’s lack of insight into the illness
 Poor provider–patient relationship
 Presence of barriers to care
 Missed appointments
 Complexity of treatment
 Cost of medication, copayment or both
Adherence is inversely proportional to the frequency of
dose, with patients taking medication on a schedule of four
times daily achieving average adherence rates of about 50%
[16]. Some clinicians propose that medication nonadherence
should be conceptualised as a diagnosable and treatable
medical condition [17]. The ability of physicians to recognize
nonadherence is poor, and interventions aimed at improving
adherence have had mixed results and are costly [15,18].
Adherence to medication regimens is an essential
prerequisite for symptom control in PD [19]. Rates of
adherence to treatment in PD mimic those of other
long-term conditions, with one research group reporting
that 51.3% of subjects missed at least one dose per week
and 20.5% of subjects missed three or more doses per
week [20]. The authors of a systematic review of factors
associated with nonadherence in PD patients reported six
clinical factors (mood disorders, cognitive impairment,
poor symptom control or reduced QoL, younger age or
longer disease duration, and regime complexity or poly-
pharmacy) and five demographic factors (lack of spouse
or partner, low income, employment status, and gender)
associated with nonadherence [19].
There are direct and indirect methods of measuring
adherence. Direct methods include directly observed
therapy, measurement of level of medicine or metabolite
of medicine in blood, and measurement of biological
markers in blood [17,21]. Indirect methods include patient
questionnaires, patient self-reports, pill counts, rates of
prescription refills, assessment of patient’s clinical re-
sponse, electronic medication monitors and patient diaries
[17,21]. Though certain methods are preferred in specific
clinical or research settings, a combination of measures
maximizes accuracy [22].
Shared decision-making
Patients are increasingly taking active roles in decisions
about major medical interventions, such as hip re-
placement surgery, and about routine decisions, such
as medication initiation [23]. However, there is evi-
dence on shared decision-making between patient and
clinician that, though patients are well-advised to learn
about the potential benefits and risks of relevant
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this is not followed in most clinical settings due to clin-
ician and patient factors [23,25,26]. In a large-scale survey
of PD patients in Sweden, researchers found that doctors
provided only a small proportion of patients with advanced
therapy information, despite patients’ interest [27].
Digital health care
The use of digital technology in daily life has become
ubiquitous. As of 2012, 76% of the UK population had
access to broadband connections and 92% of adults per-
sonally owned or used mobile phones, of which 60%
were smartphones (that is, mobile phones with features
of a handheld computer, such as internet access, data
storage, email capability and voice and video recording)
[28,29]. The authors of a recent systematic review on the
use of mobile phones in health care reported that voice
and text messaging services are used to improve health
outcomes (medication compliance, asthma symptoms,
haemoglobin A1C control, stress levels, smoking quit
rates, and self-efficacy) and processes of care (fewer
missed appointments, quicker diagnosis and treatment,
and improved teaching and training) [30]. Evidence on
the use of smartphones to improve clinical outcomes is
also gathering momentum [31]. The push to use digital
technologies in the UK National Health Service (NHS)
to improve clinical outcomes has increased in recent
years, with the Whole Systems Demonstrator study inves-
tigators reporting that telehealth services substantially
reduce mortality, the need for hospital admissions, the
number of bed days spent in hospital and the time spent
in the accident and emergency department [32].
Smartphones have been used in managing PD to assess
pervasive movement analysis remotely [33] and for
predicting the risk of falls [34]. The SMART-PD trial
was preceded by a 2 –month pilot trial carried out by
uMotif Ltd, Birkbeck University of London and The Cure
Parkinson’s Trust. Here researchers evaluated the impact
of a patient-led tracker mobile application (an ‘app’) to im-
prove medication regime adherence among PD patients
from December 2012 to March 2013 [Lakshminarayana R,
Hellman B, Addyman C, Stamford J Self-management in
long-term conditions using smartphones: A pilot rando-
mised trial in Parkinson’s disease (submitted)]. A total of
36 patients with PD took part in a 55-day pilot study and
were randomised into two groups. The limited-app group
(n = 19) received an app which had tools for daily self-
tracking on ten measures of symptom severity, general
well-being and health behaviours, along with a daily diary.
The full-app group (n = 17) received an app which had the
same tools as the limited-app group with the addition of
medication reminders and two games to assess cognition.
Participants used the app for 55 days and entered data on
at least 70% of those days.Study rationale
Despite evidence highlighting nonadherence to medication
regimes among patients with PD and a lack of evidence on
shared decision-making, there is little evidence on interven-
tions that improve adherence to PD treatment. Following
up on the findings of the 2-month pilot trial study on
patient-led use of a tracker app [35], in this follow-up study
we aim to evaluate the impact of using a Parkinson’s tracker
app (PTA) along with treatment as usual (TAU) on medi-
cation adherence in a larger number of patients across
multiple trial sites.
We hypothesise that encouraging patients to track their
symptoms and medication intake regularly may result in
increased medication adherence. Furthermore, we postu-
late that using data collected by the patient may lead to
better symptom control, an improved QoL and a higher
quality of clinical consultation.
Trial objectives
Primary objectives
Our primary objective is to investigate whether pa-
tients with PD who use the PTA in addition to TAU
show improved medication adherence.
Secondary objectives
A secondary objective is to investigate whether patients
who receive the PTA and those who receive TAU differ
in terms of QoL, quality of clinical consultation, overall
disease state, activities of daily living (ADL), beliefs about
medication and generic health-related QoL. We also aim
to investigate the experiences of those receiving the inter-
vention by gathering information from qualitative inter-
views administered by independent researchers.
Methods/Design
A single-blind, multicentre RCT will be conducted to
compare use of smartphone- and internet-enabled PTA
with TAU among patients with PD and/or their carers
across seven centres in England and Scotland. The trial
has received ethical approval from the National Re-
search Ethics Service London–Westminster Research
Ethics Committee (13/LO/1783).
Trial participants
Patients diagnosed with PD attending neurology outpatient
(OP) appointments or research clinic appointments at par-
ticipating sites will be enrolled into the trial over a 16-week
period. We have adapted the inclusion and exclusion
criteria from a similar study on treatment adherence in
PD patients [35].
To be eligible for the trial, patients must meet the fol-
lowing criteria: (1) older than 21 years of age; (2) diag-
nosed with probable, idiopathic PD; (3) prescribed one or
more antiparkinsonian medications; (4) English-speaking
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and compute and solve problems at levels of proficiency
necessary to function daily at a job and/or in ADL); (5)
have access to a smartphone and/or tablet or internet on a
daily basis at home; (6) be on a stable medication regime
(that is, not altered within the previous month and not ex-
pected to change during the period of the trial (16 weeks),
with alteration of doses of existing medications considered
to be a stable medication regime); and (7) without a
diagnosis of dementia or significant cognitive impair-
ment (as recorded in patient case file). The clinical team
will judge whether the patient has the cognitive capacity
required to participate fully in the trial (that is, read pa-
tient information, complete self-report questionnaires
and sign informed consent form).
The following are the exclusion criteria: (1) suspected
parkinsonism due to causes other than idiopathic PD,
(2) current or previous treatment with antiparkinsonian
medications (anticholinergics) for side effects of prolonged
neuroleptic treatment, (3) diagnosis of dementia or signifi-
cant cognitive impairment (as recorded in patient case
file), (4) current or previous diagnosis of mental illness as-
sociated with psychosis (schizophrenia, severe depression
with psychosis, bipolar affective disorder) (as recorded in
patient file), and (5) detrimental illness with a short life
expectancy.
Informed consent will be obtained from every trial
participant.
Outcome measures
The primary outcome measure is adherence to treatment
as determined by Morisky Medication Adherence Scale
(MMAS-8) score at 16 weeks [36,37]. The response cat-
egories are ‘yes’ or ‘no’ for each item with a dichotomous
response and a 5-point Likert response for the last item. A
‘yes’ response is scored as 1 and a ‘no’ has no score. The
primary endpoint will be the total MMAS-8 score at 16
weeks. We are collecting data from a range of secondary
outcome measures, including the following:
 Parkinson’s Disease Questionnaire (PDQ-39) to
measure QoL [38]
 Quality of consultation for PD patients (from the
Patient-Centered Questionnaire for PD [39]
 Non-Motor Symptoms Scale [40]
 Hospital Anxiety and Depression Scale [41]
 Beliefs about Medication Questionnaire [42]
In addition to the measures listed above, we will collect
demographic data at baseline, such as participant age,
duration and severity of PD (Unified Parkinson’s Disease
Rating Scale score if recorded in clinical file), medica-
tion profile (types of medication, dosage level and fre-
quency), socioeconomic status, ethnicity, comorbidities,level of education and whether medication is self-
administered or given by a spouse or carer. We also
will collect patients’ self-reported ratings and game
scores within the application.
Randomisation and masking
Eligible patients for whom consent or assent is provided
will be allocated in a 1:1 ratio to the two arms of the
study according to a computer-generated random se-
quence stratified by centre and using blocks of variable
size. The allocation sequence will be generated by the trial
statistician and will not be available to any member of the
research team until databases have been completed and
locked. In view of the established safety record of study
interventions, there will be no provision for emergency
unblinding of participants, and copies of the allocation se-
quence will not be held at the recruiting centres.
Recruitment procedures
Patients who are potentially eligible based on inclusion
criteria (except inclusion criterion 4) will be identified
by the clinical team across the seven trial sites from the
clinic’s list 6 weeks prior to upcoming outpatient ap-
pointments. An information pack containing a patient
invitation letter, a Participant Information Sheet and a
consent form will be sent to potential participants 3 to
4 weeks prior to the next OP clinic appointment or
separately with an OP clinical appointment date by
post and/or by email, along with a request to reply
within 1 week. Reminders will be sent by post and/or
email sent 1 to 2 weeks before an OP appointment to
those who fail to respond to email. At the OP appoint-
ment, the clinician will (1) recheck whether the partici-
pant has daily access to a smartphone or tablet or an
internet connection and (2) assess whether a change in
medication regime is needed. If the patient does not have
such a connection and/or needs a change in medication
regime, he or she will not be enrolled into the trial. How-
ever, these participants will be given free access to the app
once the trial is completed. Patients sign a hard copy of
the consent and complete the questionnaires at the clinic
if it is possible to give them internet access at the clinic or
if they can complete the questionnaires at home within 1
week after the OP appointment. If participants withdraw
from the trial after giving consent, they will continue to
receive the treatment they were receiving prior to the start
of the trial (that is, TAU). Data collected up to the point of
withdrawal will be retained for final analysis. Following
consent, patients are randomised to either the interven-
tion or the control group. Randomisation is carried out
with sealed randomisation envelope for each participant
generated by the trial statistician. The clinician runs
through the details of the allocation—intervention or con-
trol—with the patient and gives him or her the date for
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the course of 16 weeks until recruitment targets are
achieved. Participants in the intervention group will get a
call from their clinicians 2 weeks postrandomisation to
check if they have any difficulties with the PTA. All partic-
ipants get a call from their clinician 1 to 2 weeks prior to
the follow-up appointment to remind them of their
appointment. Participants complete the questionnaires
within 1 week after their appointment.
The trial is being carried out in adherence to the Consoli-
dated Standards of Reporting Trials (CONSORT) Statement
[43] (Figure 1), and the protocol adheres to the guidelines
for clinical trial protocols set forth in the SPIRIT 2013
Statement (Standard Protocol Items: Recommendations
for Interventional Trials) Additional file 1: Table S1, [44].
Sample size
The sample size for the smartphone- and internet-
assisted self-management and adherence tools to manageFigure 1 CONSORT flowchart for the SMART-PD trial. CONSORT, Conso
tracker app; SMART-PD, Smartphone- and internet-assisted self-managemen
as usual.Parkinson’s disease (SMART-PD) trial has been deter-
mined in a pragmatic manner based on available fund-
ing to demonstrate both the effectiveness and the ease
of implementation of the intervention. The sample size
was calculated along two dimensions: the primary
outcome (that is, MMAS-8 score) and the secondary
outcome (QoL). The main sample size calculation was
based on the primary endpoint. To detect a 1-point im-
provement on the MMAS-8 with a standard deviation
(SD) of 2.5 and 80% power at the 5% significance level
would require 200 subjects (100 in each group, 1:1
allocation). To allow for 10% loss due to dropouts and
those lost to follow-up, we would need to recruit 222
subjects (111 in each group, 1:1 allocation). The study
is also powered to detect a 6-unit difference in the sec-
ondary outcome, QoL (PDQ-39). With a SD of 9 and
80% power at the 5% significance level, 74 subjects
would be required (37 in each group, 1:1 allocation).
To allow for 10% loss due to dropouts and those lost tolidated Standards of Reporting Trials; OP, Outpatient; PTA, Parkinson’s
t and adherence tools to manage Parkinson’s disease; TAU, Treatment
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each group, 1:1 allocation). Therefore, 222 participants
will be recruited.
Intervention group
Parkinson’s tracker app
Participants allocated to receive the intervention will re-
ceive instructions to download the PTA to their Android
or iPhone smartphones or tablet devices or to access it
via a website portal within 1 day after they have attended
their outpatient appointment. The app consists primarily
of the following features:
 Using a sliding petal interface (Figure 2), participants
will adjust their daily scores on eight to tenFigure 2 Screenshot of the self-tracking interface.self-monitoring measures on a 5-point scale: water,
sleep, exercise, 5 A DAY healthy diet, mood and
energy, medication, movement, suppleness and
control. Participants who have difficulty manipulating
the flower icon due to their motor symptoms will
have the option of using an accessibility mode with a
zoom function to magnify the screen. Participants will
be able to review their scores and compare ‘petals’
against each other.
 A reminder system for patients to receive alerts and
track medication intake
 An option to generate a compiled report of data
entered by the patient over the trial period that will
serve as an aid for shared decision-making during
their follow-up outpatient appointment
 Games to track physical responsiveness (finger-tapping
task) (Figure 3) and cognition (number-size Stroop
test) (Figure 4)Finger-tapping test In the finger-tapping test, participants
have to tap the screen of the smartphone as many times as
they can in a 20-second period, alternating between two
circular targets. The game displays the participant’s cumula-
tive score. The app also records variations in responses.Number-size Stroop test In the number-size Stroop
test, the game displays two circular targets, each contain-
ing a number in the range 1 to 99 in various font sizes.
Participants have to tap the numerically larger value and
visual size information. Participants get points for correct
answers when they select the numerically larger number.
The game lasts 20 seconds and displays the cumulative
score. The app also records reaction times and variability
in responses.Tracking progress
Clinicians will have access to a dedicated web portal where
they can see participants’ progress over the trial period.
Participants will also have access to a dedicated web por-
tal. However, neither group will be able make changes to
any data. At the follow-up appointment, participants in
the PTA group will be able to generate a report compiled
from the data they have entered over the trial period to
share with their clinicians (see Figure 5).Treatment-as-usual group
They will have their regular OP clinical assessments,
including symptom review followed by a medication
review, at the start of the trial and at the end of 16
weeks. We do not expect any adverse events to occur
during the trial.
Figure 3 Screenshots of the finger-tapping test.
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The trial statistician will be blinded to the allocation of
trial participants. In the main analysis, the effect of the
interventions on the primary and secondary outcomes
will be assessed. The generalised linear model (GLM)
will be employed for analysis of the primary endpoint
(MMAS-8 at 16 weeks). The GLM model will have
treatment as the fixed effect and baseline measurementFigure 4 Screenshots of the number-size Stroop test.of the primary endpoint as the covariate. For GLM
model analysis, normal distributions will be used in the
GLM, and the mean difference in MMAS-8 with its 95%
confidence interval will be derived and reported. Model
assumptions about residuals in regression analysis will
be checked by inspection of residuals versus a fitted
values plot. In addition, adjusted analysis and subgroup
analysis with prespecified covariates will be performed
on the primary endpoint analysis.
For the secondary outcomes (QoL, depression, anxiety,
nonmotor symptoms, and degrees of depression and
anxiety), the analyses will be performed in an analogous
fashion within the framework of GLM. In addition,
summary statistics will be generated for the primary
and secondary endpoints with number (%) expressed
for binary outcomes and number, mean and SD used
for continuous outcomes.
Analysis of the primary and secondary outcomes will
be carried out in adherence to the intention-to-treat
principle (that is, the participants will remain in the
group to which they were randomised and not analysed
Figure 5 Screenshot of a sample report generated by the Parkinson’s tracker app.
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addition, supplemental per-protocol analyses will be
performed. Detailed results of statistical analysis will
be described in the statistical analysis plan, which will
be finalised before lockup of the database. The SAS 9.2
statistical software package (SAS Institute, Cary, NC,
USA) will be used for all the data analyses.
Exploratory analyses
Self-reported scores and game data from the PTA pro-
vide an opportunity to perform exploratory analysis of
patterns of day-to-day variation and correlation of
Parkinson’s symptoms with medication intake and
other health behaviours. Previous researchers have
found that daily self-tracking and data from the finger-
tapping test give a detailed and sometimes conflicting
picture of a patient’s condition compared to retrospective
self-assessment [45]. Data recorded daily within the
PTA will be used to examine correlations between vari-
ous items collected via the PTA at individual and
group levels. These scores will also be used in regres-
sion analyses against the primary and secondary outcome
measures.Qualitative evaluation
Semistructured interviews will be undertaken by an in-
dependent agency with a purposively selected subsample
of participants (n ≤ 5) to explore the process and experi-
ence of using the PTA. We will interview only participants
who consent to be interviewed. All participants who give
us consent will be pooled, and those who will be inter-
viewed will be selected at random to minimize selection
bias. Interviews will be 45 minutes in duration. The aims
are to complement the quantitative findings by obtaining
insights into the experience of using the PTA, consider
which elements of the PTA are most helpful, explore per-
ceptions of how the PTA has influenced medication taking
and explore how the PTA could be improved. Exploratory
correlational analysis will be performed on the self-report
and game score data collected by using the PTA.
Ethical considerations
We do not anticipate any serious risk to trial participants,
as we assume that patients will take their medications as
prescribed by their clinicians. However, there is a possibil-
ity that increased medication adherence in PD may lead to
a greater incidence of medication induced side effects,
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sea and impulsive and/or compulsive behaviour disorders
resulting from dopaminergic therapy for PD. We will alert
patients about these potential side effects in the Patient
Information Sheet and advise them to contact their clin-
ical team, if necessary, as part of routine clinical practice.
Trial monitoring
We will assess the impact of using self-management
tools delivered via smartphones and the web, along with
routine treatment, for 16 weeks. The trial protocol has
minimal to no risk of worsening PD progression. These
factors led us to form a monitoring group rather than a
Data Monitoring Committee. Monitoring of the trial will
be performed by the Trial Management Group (TMG),
which will consist of lead investigators from each site
and the Chief Investigator (CI) from uMotif. The CI will
call and/or email each trial site every 2 weeks to check if
there have been any issues with software and to follow
up on recruitment rates. The CI will send a monthly
update to each of the trial sites and to the NHS research
and development lead. The trial advisory board will
include members of the TMG and representatives from
The Cure Parkinson’s Trust UK and Parkinson’s UK. It
will be chaired by Dr Jon Stamford from The Cure
Parkinson’s Trust. We have scheduled three TMG
meetings—one prior to the start of the trial, one midway
through and one at the end of the trial. Any issues related
to the software, participants or the trial, including protocol
amendments, will be discussed and resolved by the TMG
at the meeting scheduled for midway through the trial.
Trial administration
Administration of the trial reflects the allocation of
responsibilities set out in the Research Governance
Framework [46]. The CI will be in charge of conducting
the trial according to the agreed protocol and in ac-
cordance with legal requirements, guidance and ac-
cepted standards of good practice; will arrange to make
findings and data accessible following expert review;
and inform participants of the research results. Lead
investigators at the trial sites will conduct the trial ac-
cording to the agreed protocol and in accordance with
legal requirements, guidance and accepted standards
of good practice; will ensure participants’ welfare while
in the study; and will arrange to make findings and
data accessible following expert review. The trial spon-
sor is responsible for establishing and keeping in place
arrangements to initiate, manage and fund the study.
Data management
Data will be stored securely on hardened servers and
backed up. To maintain data protection, the sponsor has
notified the Information Commissioner’s Office that it isa data controller and processor. No data will be shared
with anyone or any entity other than the trial team. Data
sets will be anonymised before transfer to the outcomes
assessor (that is, the trial statistician) at the end of the
trial. The trial statistician and sponsor will have access
to the final data set.
Publication policy
Reporting and dissemination
Prior to submission or application for presentation, all
manuscripts, posters, oral presentations and other reports
of the outcomes of this research effort will be approved
uMotif. All publications will include a formal acknow-
ledgement that the trial was designed by uMotif with
feedback from trial sites, and the Liverpool School of
Tropical Medicine and that it was or is being carried
out by uMotif and all trial sites. We will also acknowledge
that the trial was supported by The Cure Parkinson’s
Trust and Parkinson’s UK and that the study was commis-
sioned by NHS Midlands and East and funded by the UK
Department of Health.
Authorship
The authorship of manuscripts, posters, oral presentations
and any other reports of the results of this study will be
guided by the criteria for authorship formulated by the
International Committee of Medical Journal Editors as
published in its Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work in
Medical Journals [47]. According to these requirements,
the authors should meet the following criteria: (1) Each
author should have participated sufficiently in the work
to take public responsibility for the content; and (2)
authorship credit should be based only on substantial
contributions (a) to the conception and design or analysis
and interpretation of data; (b) to the drafting of the manu-
script or to revising it critically for important intellectual
content; and (c) by giving final approval of the version to
be published. Conditions 2a), 2b) and 2c must be met. A
plain English summary of the findings will be sent to all
trial participants.
Discussion
There is a paucity of evidence on interventions to enhance
treatment adherence in PD. Unlike previous studies in
which researchers investigated adherence to therapy pro-
grammes, SMART-PD uses resources that patients and
their carers and/or partners have (i.e. a smartphone or
tablet device). By ensuring that the intervention is in-
troduced in routine clinical practice with minimal need
for additional resources, our aim in the SMART-PD
trial is to demonstrate that adherence to treatment and
quality of clinical consultation can be improved in a
cost-effective manner. The subjective nature of the
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Patients may over- or underreport their true health status,
depending on the trial arm to which they are assigned. To
reduce this bias, baseline primary outcome measures will
be completed within a maximum of 2 weeks of random-
isation. The nature of the SMART-PD intervention does
not allow masking of study participants blinded to their
group allocation. Therefore, secondary outcomes at
baseline (completed postrandomisation) and all follow-
up study outcomes will not be blinded. The SMART-PD
intervention is aimed at PD patients who have smart-
phones and/or tablet devices or internet access, thereby
omitting those who do not have such access. To reduce
this selection bias, we are including those patients whose
carers and/or partners have a smartphone. However, with
rapid penetration of smartphones in the UK, we expect
this limitation to decrease rapidly. If effective, the trial
results will demonstrate improved outcomes with the use
of innovative smartphone technology for patients with
long-term conditions and the clinicians who treat them.
Trial status
Recruitment began 12 August 2014. It is anticipated that
study recruitment will be completed by 31 October 2014
and that the trial will conclude by 30 April 2015.
Additional file
Additional file 1: Table S1. SPIRIT 2013 Checklist: Recommended items
to address in a clinical trial protocol and related documents.
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